Corporate



Lonza Group Ltd Muenchensteinerstrasse 38 4002 Basel, Switzerland www.lonza.com

News Release

Lonza Prices CHF 325 Million Dual Tranche Straight Bonds

Basel, 19 August 2015 – Lonza Swiss Finance Ltd, a wholly-owned company of Lonza Group Ltd, Basel ("Lonza"), announces the pricing of its dual tranche CHF 325 million straight bonds. The bonds have a maturity of 5 and 8 years respectively with coupons of 0.625% and 1.250%. The issuer is Lonza Swiss Finance Ltd, Basel, and the bonds will be guaranteed by Lonza. Lonza will apply for the listing of the bonds on the SIX Swiss Exchange. The proceeds of the bonds will be used for the refinancing of existing debt.

Key data:

Issue size 5 year bond: CHF 150 million
Expected payment date: 22 September 2015

Maturity: 22 September 2020 (5 years)

Issue price: 100.135 percent
Redemption price: 100 percent
Coupon: 0.625 percent p.a.

Joint Lead Managers: Credit Suisse AG, UBS AG and Zürcher Kantonalbank

Co-Manager: Basler Kantonalbank

Issue size 8 year bond: CHF 175 million Expected payment date: 22 September 2015

Maturity: 22 September 2023 (8 years)

Issue price: 100.133 percent
Redemption price: 100 percent
Coupon: 1.250 percent p.a.

Joint Lead Managers: Credit Suisse AG, UBS AG and Zürcher Kantonalbank

Co-Manager: Basler Kantonalbank

Corporate



Lonza Group Ltd Muenchensteinerstrasse 38 4002 Basel, Switzerland www.lonza.com

News Release

About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

Not only are we a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities and approximately 9,800 full-time employees worldwide. The company generated sales of about CHF 3.64 billion in 2014 and is organized into two market-focused segments: Pharma&Biotech and Specialty Ingredients. Further information can be found at www.lonza.com.

Lonza Contact Information

Lonza Group Ltd
Head Investor Relations
Dirk Oehlers
Dominik Werner
Tel +41 61 316 8540
Fax +41 61 316 9540
Dominik Werner
Fax +41 61 316 9540
Dominik Werner
Tel +41 61 316 9540
Fax +41 61 316 9540
Fax +41 61 316 9540
Fax +41 61 316 9840
Constance Ward
Fax +41 61 316 9840
Fax +41 61 316 9840
Constance.ward@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.